Yadav Sankalp
Medicine, Shri Madan Lal Khurana Chest Clinic, New Delhi, IND.
Cureus. 2024 Sep 1;16(9):e68421. doi: 10.7759/cureus.68421. eCollection 2024 Sep.
India has a high burden of drug-resistant tuberculosis (DR-TB) cases. The management of this severe form of TB is associated with a number of issues like long treatment durations, high pill burden, and multiple adverse drug reactions. Efforts are on through various research studies and trials for finding solutions to the issues linked to the current drug regimens against drug-resistant tuberculosis. One such remarkable development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against two of the most severe forms of tuberculosis, i.e., multidrug- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB). This editorial throws light on this newer regimen and discusses the same in the Indian context.
印度耐药结核病（DR-TB）病例负担沉重。这种严重形式的结核病管理存在诸多问题，如治疗时间长、服药负担重以及多种药物不良反应。目前正在通过各种研究和试验努力寻找解决与当前耐药结核病药物治疗方案相关问题的办法。一项显著进展是引入了基于贝达喹啉、普瑞玛尼、利奈唑胺和莫西沙星（BPaLM）的治疗方案，以对抗两种最严重的结核病形式，即耐多药结核病和广泛耐药结核病（MDR-TB和XDR-TB）。这篇社论阐述了这种新的治疗方案，并在印度背景下对其进行了讨论。
